STOCK TITAN

Savara Announces New Employment Inducement Grant

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focusing on rare respiratory diseases, has announced the grant of inducement awards to four new employees. The Compensation Committee of Savara's Board of Directors granted these awards on October 17, 2024, consisting of:

  • Options to purchase 95,000 shares of common stock
  • Restricted stock units (RSUs) covering 95,000 shares of common stock

These equity awards were granted under the Savara Inc. 2021 Inducement Equity Incentive Plan, in compliance with NASDAQ Listing Rules. The options have an exercise price of $3.65 per share, a 10-year term, and vest quarterly over four years. The RSUs vest in full after two years, subject to continued employment.

Savara Inc. (Nasdaq: SVRA), un'azienda biofarmaceutica in fase clinica che si concentra su malattie respiratorie rare, ha annunciato l'assegnazione di premi di indennità a quattro nuovi dipendenti. Il Comitato di Compensazione del Consiglio di Amministrazione di Savara ha concesso questi premi il 17 ottobre 2024, consistenti in:

  • Opzioni per acquistare 95.000 azioni ordinarie
  • Unità di azioni vincolate (RSU) coprenti 95.000 azioni ordinarie

Questi premi azionari sono stati concessi nell'ambito del Piano di Incentivazione Azionaria di Indennità 2021 di Savara Inc., in conformità con le Norme di Quotazione NASDAQ. Le opzioni hanno un prezzo di esercizio di $3.65 per azione, una durata di 10 anni e vengono maturate trimestralmente nel corso di quattro anni. Le RSU si maturano completamente dopo due anni, soggette a continuazione del rapporto di lavoro.

Savara Inc. (Nasdaq: SVRA), una compañía biofarmacéutica en etapa clínica centrada en enfermedades respiratorias raras, ha anunciado la concesión de premios de inducción a cuatro nuevos empleados. El Comité de Compensación de la Junta Directiva de Savara otorgó estos premios el 17 de octubre de 2024, que consisten en:

  • Opciones para comprar 95,000 acciones ordinarias
  • Unidades de acciones restringidas (RSU) que cubren 95,000 acciones ordinarias

Estos premios de capital se otorgaron bajo el Plan de Incentivos de Capital de Inducción 2021 de Savara Inc., en cumplimiento de las Reglas de Cotización de NASDAQ. Las opciones tienen un precio de ejercicio de $3.65 por acción, un plazo de 10 años y se devengan trimestralmente durante cuatro años. Las RSU se devengan en su totalidad después de dos años, sujeto a la continuidad del empleo.

사바라 주식회사(Savara Inc.)(Nasdaq: SVRA)는 드문 호흡기 질환에 초점을 맞춘 임상 단계의 생물 의약품 회사로, 네 명의 신입 직원에게 유인 보상을 수여한다고 발표했습니다. 사바라 이사회의 보상 위원회는 2024년 10월 17일에 이 보상을 승인했으며, 내용은 다음과 같습니다:

  • 신주 95,000주를 매수할 수 있는 옵션
  • 신주 95,000주를 커버하는 제한 주식 단위(RSU)

이 주식 보상은 사바라 주식회사 2021 유인 주식 인센티브 계획에 따라 NASDAQ 상장 규정 준수하에 수여되었습니다. 옵션의 행사 가격은 주당 $3.65이며, 10년의 기간을 가지며, 4년 동안 분기별로 권리가 발생합니다. RSU는 2년 후 전액 발생하며, 계속 고용이 유지되어야 합니다.

Savara Inc. (Nasdaq: SVRA), une société bio-pharmaceutique en phase clinique axée sur les maladies respiratoires rares, a annoncé l'octroi de récompenses d'induction à quatre nouveaux employés. Le Comité de Rémunération du Conseil d'Administration de Savara a accordé ces récompenses le 17 octobre 2024, consistant en :

  • Options d'achat de 95 000 actions ordinaires
  • Unités d'actions restreintes (RSU) portant sur 95 000 actions ordinaires

Ces récompenses en capital ont été accordées dans le cadre du Plan d'Incitation d'Induction en Capital 2021 de Savara Inc., en conformité avec les Règles d'Enregistrement NASDAQ. Les options ont un prix d'exercice de 3,65 $ par action, une durée de 10 ans et sont acquises trimestriellement sur quatre ans. Les RSU sont entièrement acquises après deux ans, sous réserve de la continuité de l'emploi.

Savara Inc. (Nasdaq: SVRA), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf seltene Atemwegserkrankungen konzentriert, hat die Vergabe von Anreizvergütungen an vier neue Mitarbeiter bekannt gegeben. Der Vergütungsausschuss des Vorstandes von Savara gewährte diese Auszeichnungen am 17. Oktober 2024 und umfasst:

  • Optionen zum Kauf von 95.000 Stammaktien
  • Restricted Stock Units (RSUs) für 95.000 Stammaktien

Diese Eigenkapitalvergaben wurden im Rahmen des Savara Inc. 2021 Inducement Equity Incentive Plans in Übereinstimmung mit den NASDAQ-Notierungsregeln gewährt. Die Optionen haben einen Ausübungspreis von $3,65 pro Aktie, eine Laufzeit von 10 Jahren und werden vierteljährlich über einen Zeitraum von vier Jahren fällig. Die RSUs werden nach zwei Jahren vollständig fällig, vorausgesetzt, das Arbeitsverhältnis bleibt bestehen.

Positive
  • Attraction of new talent with equity incentives
  • Alignment of employee interests with company performance through stock options and RSUs
Negative
  • Potential dilution of existing shareholders' equity

LANGHORNE, Pa.--(BUSINESS WIRE)-- Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to four new employees.

On October 17, 2024, the Compensation Committee of Savara's Board of Directors granted the inducement awards to four new employees who recently joined the Company. The inducement awards consist of options to purchase an aggregate of 95,000 shares of the Company’s common stock and restricted stock units (RSUs) covering an aggregate of 95,000 shares of the Company’s common stock. These equity awards were granted under the Savara Inc. 2021 Inducement Equity Incentive Plan pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules as an inducement material to the employees’ acceptance of employment with the Company.

The options have an exercise price of $3.65 per share, the closing trading price of the Company's common stock on the NASDAQ Global Market on the grant date. Each option has a 10-year term and vests as to 1/16th of the number of shares subject to the option on each quarterly anniversary of the employee’s first day of employment, subject to the employee’s continued employment on each such vesting date. The RSUs vest in full on the two-year anniversary of the employee’s first day of employment, subject to the employee’s continued employment on such vesting date.

About Savara

Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim inhalation solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is delivered via an investigational eFlow® Nebulizer System (PARI Pharma GmbH). Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at www.savarapharma.com. (X, formerly known as Twitter: @SavaraPharma, LinkedIn: www.linkedin.com/company/savara-pharmaceuticals/).

Savara Inc. IR & PR

Anne Erickson (anne.erickson@savarapharma.com)

(512) 851-1366

Source: Savara Inc.

FAQ

What type of inducement awards did Savara (SVRA) grant to new employees?

Savara (SVRA) granted options to purchase 95,000 shares of common stock and restricted stock units (RSUs) covering 95,000 shares of common stock to four new employees.

When were the inducement awards granted by Savara (SVRA)?

The inducement awards were granted by Savara's (SVRA) Compensation Committee on October 17, 2024.

What is the exercise price of the stock options granted by Savara (SVRA)?

The stock options granted by Savara (SVRA) have an exercise price of $3.65 per share, which was the closing trading price of the company's common stock on the NASDAQ Global Market on the grant date.

How do the stock options and RSUs vest for Savara's (SVRA) new employees?

The stock options vest 1/16th quarterly over four years, while the RSUs vest in full on the two-year anniversary of the employee's first day of employment, subject to continued employment.

Savara Inc.

NASDAQ:SVRA

SVRA Rankings

SVRA Latest News

SVRA Stock Data

587.62M
164.60M
4.72%
92.97%
5.33%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
AUSTIN